Business
ANGLE presentation via Investor Meet Company
ANGLE presentation via Investor Meet Company.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n21 April 2023\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nPRESENTATION VIA INVESTOR MEET COMPANY\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce it will be presenting via the Investor Meet Company platform at 11:00 am (BST) on Friday 28 April 2023.\n \nThe presentation by Andrew Newland and Ian Griffiths will give existing and prospective investors an opportunity to hear an overview presentation of the Company's current activities and strategy. There will also be time allocated to answering questions submitted by shareholders and interested investors.\n \nQuestions can be submitted in advance of the presentation via the Investor Meet Company dashboard up until 5:00 pm (BST) Wednesday 26 April 2023. Questions will be grouped and addressed under key themes. Please note that there will be no facility to ask questions during the presentation.\n \nInvestors can register for the ANGLE plc presentation via Investor Meet Company using the link https://www.investormeetcompany.com/angle-plc/register-investor\n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Chief Financial Officer\nAndrew Holder, Head of Investor Relations\n \n\n\n \n \n \n \n\n\n\n\n \nBerenberg (NOMAD and Joint Broker)\nToby Flaux, Ciaran Walsh, Milo Bonser\n\n\n \n+44 (0) 20 3207 7800\n\n\n\n\n \nJefferies (Joint Broker)\nThomas Bective, Shaam Vora\n\n\n \n+44 (0) 20 7029 8000\n \n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin\nMatthew Ventimiglia (US)\n\n\n \n \n+44 (0) 203 727 1000\n+1 (212) 850 5624\n\n\n\n\n \n \nFor Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/\n \n \nNotes for editors\n \nAbout ANGLE plc www.angleplc.com \nANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected circulating tumor cell (CTC) harvesting technology is known as the Parsortix® system.\n \nANGLE's Parsortix® system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to...